The purpose of the study is to confirm whether MV140 is safe and helpful in reducing repeated urinary tract infections. The trial lasts about 15 months after treatment begins. Over this time, participants are followed for new infection episodes, and study visits are used to check symptoms and general health. The study also looks at side effects and how the treatment affects daily life.

The vaccine used in the study contains inactive forms of common bacteria that can cause urinary tract infections: Klebsiella pneumoniae, Escherichia coli, Enterococcus faecalis, and Proteus vulgaris. These bacteria are not alive in the vaccine. The treatment is given as a small spray under the tongue.

The purpose of the study is to determine whether a shorter, 7‑day course of the antibiotic works as well as the standard 14‑day course in achieving a cure of the infection.

Participants are randomly assigned to receive either the short or the longer treatment. After finishing the medication, they are followed up with visits about two weeks and four weeks later to check whether symptoms have resolved, whether the infection has returned, and whether any side effects have occurred. “Clinical cure” means the patient’s signs and symptoms have returned to normal and no additional antibiotics are needed.

Participants in the study will be assigned to receive different treatments to prevent further infections. One group will receive methenamine hippurate, while other groups will receive standard antibiotic treatments such as cefalexin, sulfamethoxazole and trimethoprim, or fosfomycin trometamol. These medications are taken by mouth over a period of time to see which method is better at reducing the number of symptomatic infection episodes and preventing the growth of multidrug-resistant bacteria, which are germs that are difficult to kill with standard medicines.

During the study, participants will be monitored to see how well the different antibiotic treatments work to clear the infection and reduce symptoms such as fever. The course of the study involves comparing the effectiveness of the oral and injection combination against the existing hospital methods to determine if the new approach is just as effective in achieving a clinical cure.

The treatments used in this study include various antibiotics that can be given either through a vein (intravenous) or by mouth. Some of these medications are amoxicillin, ciprofloxacin, ceftriaxone, and several others. The study starts with giving antibiotics through a vein until the fever goes away and the patient’s condition improves. Then, depending on which group the patient is assigned to, they will either receive pivmecillinam tablets or continue with standard treatment.

The study will check how well the treatments work by monitoring if symptoms improve, if the fever stays away, and if the infection clears up. The researchers will also look at side effects of the medications, how the treatments affect bacteria in the digestive system, and which treatment approach is more cost-effective. The study is expected to run for several years, starting in 2025.

The trial will compare the effects of FMT with other treatments, including Monuril 3000 mg Granulat, which contains the active ingredient fosfomycin trometamol, and Vancomycin, an antibiotic. Additionally, a product called INTESTIFIX 001, derived from donor stool, will be used. Some participants will receive a placebo, which looks like the real treatment but does not contain the active ingredients. The study will monitor participants over a period to see how many new urinary tract infections occur and how quickly they happen after treatment.

Throughout the study, participants will be observed for any changes in their symptoms and overall quality of life. The trial will also assess the safety of FMT by reviewing any side effects or new medical conditions that arise during the follow-up period. The goal is to understand how effective FMT is in preventing recurrent urinary tract infections and to identify factors that contribute to its success.

The purpose of this study is to learn more about how these medications work in the body, as well as to check their safety and how well they are tolerated by the infants. The study will be conducted in two parts, where the infants will receive either a single dose or multiple doses of the medications. The medications will be given through an intravenous infusion, which means they will be delivered directly into the bloodstream through a vein. The study will monitor the infants closely to see how their bodies process the medications and to watch for any side effects or reactions.

Throughout the study, researchers will collect information on how the medications affect the infants’ infections and overall health. This includes checking the levels of the medications in the blood, observing any side effects, and assessing the infants’ recovery from the infections. The study aims to provide valuable information that could help improve the treatment of serious bacterial infections in very young children.

Participants in the study will receive either the medication being tested or a different form of the same antibiotic, known as fosfomycin trometamol. The study is designed to compare the two forms to see if fosfomycin calcium is as effective as fosfomycin trometamol in treating uUTI. The trial will be conducted in a way that neither the participants nor the researchers know which treatment is being given, ensuring unbiased results.

The study will take place over a period of time, during which participants will be monitored for their response to the treatment. This includes checking for the resolution of uUTI symptoms and ensuring that the bacterial infection is reduced. The trial aims to provide valuable information on the effectiveness of fosfomycin calcium in treating uncomplicated urinary tract infections in women.

The main purpose of this research is to examine how safe and well-tolerated Vabomere is when used in children aged between 3 months and 12 years who have these urinary tract infections. During the study, participants will need to stay in the hospital initially and receive the medication through an intravenous infusion for at least 3 days. The total treatment period may last between 7 to 14 days.

Throughout the study, doctors will monitor the children’s health by checking their blood and urine samples, vital signs, and any side effects that may occur. They will also look at how the medication moves through the body and how well it works in treating the infection. The medication will be given at regular intervals, with careful attention to the appropriate dose for each child.

The trial will compare the treatment combinations of cefepime/nacubactam and aztreonam/nacubactam against the best available therapy currently used for these infections. Cefepime and aztreonam are antibiotics, while nacubactam is a substance that helps these antibiotics work better against resistant bacteria. The study will involve administering these treatments through an intravenous infusion, which means the medication is given directly into a vein.

Participants in the study will receive one of the treatment combinations or the best available therapy for up to 14 days. The goal is to determine which treatment is most effective in achieving overall treatment success across all the infection types mentioned. The study will also monitor the safety of the treatments to ensure they are safe for use in patients. This trial aims to provide valuable information that could lead to better treatment options for these challenging infections.

The purpose of the study is to evaluate how well these treatments work and how safe they are for patients with these infections. Participants in the study will receive one of the treatment combinations or a placebo, and their progress will be monitored over a period of time. The study will involve regular visits to the clinic for check-ups and assessments to see how the infection is responding to the treatment. The goal is to find out which treatment is most effective in curing the infection and preventing it from coming back.

Throughout the study, participants will be closely observed to ensure their safety and to monitor any side effects that may occur. The study aims to provide valuable information that could help improve the treatment of these types of infections in the future. By comparing the different treatment options, researchers hope to identify the best approach for managing cUTI and AP, ultimately leading to better outcomes for patients.

Participants in the study will receive treatment for up to 14 days. The study will monitor the clinical response, which means checking if the infection is cured both clinically and microbiologically, 5 to 7 days after the treatment ends. This is known as the test of cure. The study will also look at other outcomes, such as the rate of clinical cure in different groups of patients, the eradication of bacteria, and any side effects related to the treatment. Additionally, the study will track hospital readmissions, any relapses or reinfections, and other health-related events up to 90 days after treatment begins.

The study aims to provide valuable information on whether IV Fosfomycin is as effective as other treatments for these complicated infections. This could help improve treatment options for patients with these challenging infections in the future.

The purpose of this research is to determine how well oral tebipenem pivoxil works compared to intravenous imipenem-cilastatin in treating these urinary tract infections. The study will measure whether the infections are cured and if the bacteria causing the infections are eliminated. The medications will be given to adult patients who are in the hospital.

During the study, patients will receive treatment for up to 10 days. The study team will monitor patients’ symptoms and take urine samples to check if the infection is responding to treatment. They will also check for any side effects from the medications. After the treatment period ends, patients will have follow-up visits to ensure the infection has been properly treated.

The purpose of the study is to evaluate the pharmacokinetics (PK) – how the medicine moves through the body – as well as safety and how well it is tolerated. Children will be treated for a short period, with blood samples taken to check drug levels and regular checks of liver and kidney function. After the treatment ends, follow‑up visits will assess whether the infection has cleared and whether any side effects occurred.

The purpose of the study is to determine if these alternative antibiotics can safely and effectively treat febrile UTIs, which are UTIs accompanied by fever, caused by ESBL-producing bacteria. Participants in the study will initially receive intravenous antibiotics for a few days. Once their condition is stable, they will switch to oral antibiotics. The study will monitor the participants’ health to ensure the infection is resolved and no further antibiotic treatment is needed.

Throughout the study, participants will be observed for any signs of the infection returning and for any side effects from the antibiotics. The study will also check if the bacteria are still present in urine or stool samples after treatment. The goal is to find a reliable oral antibiotic treatment that can be used instead of the more commonly used antibiotics, which may not be effective against these resistant bacteria. The study will help doctors understand which antibiotics can be safely used to treat these challenging infections.